<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124161</url>
  </required_header>
  <id_info>
    <org_study_id>B1851138</org_study_id>
    <nct_id>NCT02124161</nct_id>
  </id_info>
  <brief_title>Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.</brief_title>
  <official_title>A Phase 4, Randomized, Double-blind Trial To Evaluate The Immunogenicity And Safety Of A 13-valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Seasonal Inactivated Influenza Vaccine In Adults 50 Years And Older Who Received 1 Or More Doses Of 23-valent Pneumococcal Polysaccharide Vaccine Prior To Study Enrollment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity and safety of 13-valent
      pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated
      influenza vaccine to adults 50 years and older who have previously received 23-valent
      pneumococcal polysaccharide vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes</measure>
    <time_frame>1 month after Vaccination 1 for 13vPnC+QIV/Placebo, 1 Month After Vaccination 2 for Placebo+QIV/13vPnC</time_frame>
    <description>Serotype-specific OPA GMTs for each of the 13 pneumococcal common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were logarithmically transformed for analysis. Confidence intervals (CIs) for GMT were back-transformed based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here, &quot;number of participants analyzed&quot; signifies the participants who were evaluable at this timepoint and &quot;n&quot; signifies participants with a determinate OPA titer to the given serotype.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemagglutination Inhibition Assay (HAI) Geometric Mean Titers (GMTs) for Each Influenza Virus Strain in Quadrivalent Influenza Vaccine (QIV)</measure>
    <time_frame>1 month after Vaccination 1</time_frame>
    <description>HAI GMTs were computed for assay titers collected 1 month after Vaccination 1 by vaccine sequence for each influenza virus strain (A/H1N1, A/H3N2, B/Brisbane and B/Massachusetts). CIs were back-transformations of a CI based on the Student t distribution for the mean logarithm of the titers. HAI GMTs were calculated using all participants with available data for the specified blood draw. Here, &quot;number of participants analyzed&quot; signifies participants with a determinate HAI titer to the given strain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 1</measure>
    <time_frame>Within 28 to 42 days after Vaccination 1</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 2</measure>
    <time_frame>Within 28 to 42 days after Vaccination 2</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After 13vPnC Vaccination</measure>
    <time_frame>Baseline (Vaccination 1) up to 28 to 42 Days after Vaccination 2</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) at the 6-Month Follow-up</measure>
    <time_frame>Within 168 to 196 days after Vaccination 2</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibody Titer Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ)</measure>
    <time_frame>1 Month After Vaccination 1 for 13vPnC+QIV/Placebo, 1 month after Vaccination 2 for Placebo+QIV/13vPnC</time_frame>
    <description>Percentage of participants achieving predefined OPA antibody titer &gt;= LLOQ for each of the 13 pneumococcal serotypes (LLOQs for each serotype OPA were set as- serotype 1: 18; serotype 3: 12; serotype 4: 21; serotype 5: 29; serotype 6A: 37; serotype 6B: 43; serotype 7F: 210; serotype 9V: 345; serotype 14: 35; serotype 18C: 31; serotype 19A: 18; serotype 19F: 48; and serotype 23F: 13) determined in blood samples of all participants were calculated. Exact, 2-sided 95% CIs based on the observed percentage of participants were determined by using Clopper and Pearson method. OPA titers were calculated using all participants with available data from 1 month after 13vPnC vaccination blood draw. Here, &quot;number of participants analyzed&quot; signifies the participants who were evaluable at this timepoint and &quot;n&quot; signifies participants with valid and determinate assay results to the specified serotype.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 1 to Immediately Before 13vPnC Vaccination 1</measure>
    <time_frame>Immediately before Vaccination 1, 1 month after Vaccination 1</time_frame>
    <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 1 month after Vaccination 1 to before Vaccination 1 were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before Vaccination 1 and 1 month after Vaccination 1 blood draws. Here, &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both the given visits. Number of participants who received at least 1 dose of 13vPnC during Vaccination 1 were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 2 to Immediately Before 13vPnC Vaccination 2</measure>
    <time_frame>Immediately before Vaccination 2, 1 month after Vaccination 2</time_frame>
    <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 1 month after Vaccination 2 to before Vaccination 2 (1 month after Vaccination 1) were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before Vaccination 2 and 1 month after Vaccination 2 blood draws. Here, &quot;number of participants analyzed&quot; signifies total participants who were evaluable at this timepoint and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both the given visits. Number of participants who received at least 1 dose of 13vPnC during Vaccination 2 were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Seroconversion in Hemagglutination Inhibition Assay (HAI) Titers</measure>
    <time_frame>Immediately before Vaccination 1, 1 month after Vaccination 1</time_frame>
    <description>Percentage of participants achieving seroconversion in HAI titers was defined as the percentage of participants with either before Vaccination 1 (pre-vaccination 1) HAI titer less than &lt;1:10 and after Vaccination 1 (post-vaccination 1) HAI titer &gt;=1:40 or before Vaccination 1 (pre-vaccination 1) HAI titer &gt;=1:10 and a minimum 4-fold rise in after Vaccination 1 (post-vaccination 1) HAI antibody titer with respect to before Vaccination 1 (pre-vaccination) titer for influenza virus strains. Here, &quot;number of participants analyzed&quot; signifies the participants who were evaluable at this timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) in Hemagglutination Inhibition Assay (HAI) 1 Month After Vaccination 1 to Immediately Before Vaccination 1</measure>
    <time_frame>Immediately before Vaccination 1, 1 month after Vaccination 1</time_frame>
    <description>Fold rise 1 month after Vaccination 1 to before Vaccination 1 was calculated for each influenza virus strain (A/H1N1, A/H3N2, B/Brisbane and B/Massachusetts). GMFRs were calculated using all participants with available data from both the specified blood draws. CI for the GMFRs were back transformations of a CI based on the Student t distribution for mean fold rise. Here, &quot;number of participants analyzed&quot; signifies participants with valid and determinate assay results for specified strain at both the specified blood draws.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">882</enrollment>
  <condition>PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE</condition>
  <arm_group>
    <arm_group_label>13vPnC+SIIV/Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+SIIV/13vPnC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.</description>
    <arm_group_label>13vPnC+SIIV/Placebo</arm_group_label>
    <other_name>13vPnC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal Inactivated Influenza Vaccine</intervention_name>
    <description>One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.</description>
    <arm_group_label>13vPnC+SIIV/Placebo</arm_group_label>
    <other_name>SIIV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.</description>
    <arm_group_label>13vPnC+SIIV/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.</description>
    <arm_group_label>Placebo+SIIV/13vPnC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal Inactivated Influenza Vaccine</intervention_name>
    <description>One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.</description>
    <arm_group_label>Placebo+SIIV/13vPnC</arm_group_label>
    <other_name>SIIV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.</description>
    <arm_group_label>Placebo+SIIV/13vPnC</arm_group_label>
    <other_name>13vPnC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Evidence of a personally signed and dated informed consent document (ICD) indicating
             that the subject has been informed of all pertinent aspects of the study.

          2. Male or female adults 50 years of age or older.

          3. Documented vaccination with 1 or more prior doses of 23vPS, the last given at least 1
             year prior to study enrollment.

          4. Negative urine pregnancy test for all female subjects who are of child bearing
             potential.

        Exclusion Criteria:

          1. Previous vaccination with Prevnar®, Prevnar 13®, or any other investigational
             pneumococcal conjugate vaccine.

          2. History of severe adverse reactions associated with any vaccine or vaccine-related
             component.

          3. Allergic to egg proteins (egg or egg products) and chicken proteins.

          4. History of Guillain-Barré syndrome.

          5. Vaccination with any influenza vaccine within 6 months (182 days) before
             investigational product administration.

          6. Documented S pneumoniae infection within the past 5 years before investigational
             product administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research (Formerly Accelovance)</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Vaccine Study Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanante South. Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Pemanente Santa Clara</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research, LLC</name>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <zip>46545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc/Ridge Family Practice</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials, Inc.</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada, LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Medical Associates</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research, Inc.</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC d/b/a PMG Research of Cary</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmQuest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Hickory, LLC</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America, Inc.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Winston-Salem</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prestige Clinical Research</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians, Inc.</name>
      <address>
        <city>Carnegie</city>
        <state>Pennsylvania</state>
        <zip>15106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brandywine Clinical Research</name>
      <address>
        <city>Downingtown</city>
        <state>Pennsylvania</state>
        <zip>19335</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charleston</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine and Pediatric Associates of Bristol, PC</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostics Research Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Jordan River Family Medicine</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1851138&amp;StudyName=Concomitant%20administration%20of%2013-valent%20Pneumococcal%20Conjugate%20Vaccine%20%2813vPnC%29%20with%20influenza%20vaccine%20in%2023-valent%20Pneumococcal%20Polysaccharid</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <results_first_submitted>May 23, 2016</results_first_submitted>
  <results_first_submitted_qc>May 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 1, 2016</results_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal polysaccharide vaccine</keyword>
  <keyword>13-valent pneumococcal conjugate vaccine</keyword>
  <keyword>invasive pneumococcal disease</keyword>
  <keyword>flu vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>882 participants who were greater than or equal to (&gt;=) 50 years of age and previously vaccinated with at least 1 dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) were randomized in this study but 6 participants (2 participants in 13vPnC+QIV/Placebo arm and 4 participants in Placebo+QIV/13vPnC arm) were randomized but not vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC+QIV/Placebo</title>
          <description>Participants received 0.5 milliliter (mL) single dose of 13-valent pneumococcal conjugate (13vPnC) vaccine intramuscularly along with a dose of quadrivalent influenza vaccine (QIV, as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
        </group>
        <group group_id="P2">
          <title>Placebo+QIV/13vPnC</title>
          <description>Participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection as per official recommendations at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="441"/>
                <participants group_id="P2" count="441"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 1</title>
              <participants_list>
                <participants group_id="P1" count="439"/>
                <participants group_id="P2" count="437"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 2</title>
              <participants_list>
                <participants group_id="P1" count="431"/>
                <participants group_id="P2" count="432"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="425"/>
                <participants group_id="P2" count="426"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other unspecified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Does not meet entrance criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer meets eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who received at least 1 dose of vaccination.</population>
      <group_list>
        <group group_id="B1">
          <title>13vPnC+QIV/Placebo</title>
          <description>Participants received 0.5 milliliter (mL) single dose of 13-valent pneumococcal conjugate (13vPnC) vaccine intramuscularly along with a dose of quadrivalent influenza vaccine (QIV, as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
        </group>
        <group group_id="B2">
          <title>Placebo+QIV/13vPnC</title>
          <description>Participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection as per official recommendations at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="439"/>
            <count group_id="B2" value="437"/>
            <count group_id="B3" value="876"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.9" spread="9"/>
                    <measurement group_id="B2" value="66.4" spread="8.85"/>
                    <measurement group_id="B3" value="66.7" spread="8.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="234"/>
                    <measurement group_id="B2" value="249"/>
                    <measurement group_id="B3" value="483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes</title>
        <description>Serotype-specific OPA GMTs for each of the 13 pneumococcal common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were logarithmically transformed for analysis. Confidence intervals (CIs) for GMT were back-transformed based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here, &quot;number of participants analyzed&quot; signifies the participants who were evaluable at this timepoint and &quot;n&quot; signifies participants with a determinate OPA titer to the given serotype.</description>
        <time_frame>1 month after Vaccination 1 for 13vPnC+QIV/Placebo, 1 Month After Vaccination 2 for Placebo+QIV/13vPnC</time_frame>
        <population>Evaluable immunogenicity population: eligible, randomized participants of 50 years of age or above, received all study vaccinations in assigned sequence with expected concomitant vaccination, had at least 1 valid, determinate assay results, had pre and post vaccination blood drawn within protocol-specified time frames, no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC+QIV/Placebo</title>
            <description>Participants received 0.5 milliliter (mL) single dose of 13-valent pneumococcal conjugate (13vPnC) vaccine intramuscularly along with a dose of quadrivalent influenza vaccine (QIV, as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+QIV/13vPnC</title>
            <description>Participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection as per official recommendations at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes</title>
          <description>Serotype-specific OPA GMTs for each of the 13 pneumococcal common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were logarithmically transformed for analysis. Confidence intervals (CIs) for GMT were back-transformed based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here, &quot;number of participants analyzed&quot; signifies the participants who were evaluable at this timepoint and &quot;n&quot; signifies participants with a determinate OPA titer to the given serotype.</description>
          <population>Evaluable immunogenicity population: eligible, randomized participants of 50 years of age or above, received all study vaccinations in assigned sequence with expected concomitant vaccination, had at least 1 valid, determinate assay results, had pre and post vaccination blood drawn within protocol-specified time frames, no major protocol violations.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n= 419, 417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="65.0" upper_limit="87.0"/>
                    <measurement group_id="O2" value="83" lower_limit="71.1" upper_limit="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n= 422, 418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="36.2" upper_limit="46"/>
                    <measurement group_id="O2" value="49" lower_limit="43.6" upper_limit="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n= 412, 417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="587" lower_limit="489.9" upper_limit="702.5"/>
                    <measurement group_id="O2" value="824" lower_limit="692.2" upper_limit="980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n= 423, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="83.8" upper_limit="111.7"/>
                    <measurement group_id="O2" value="101" lower_limit="86.6" upper_limit="117.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n= 420, 415)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="953" lower_limit="805.7" upper_limit="1126.3"/>
                    <measurement group_id="O2" value="1413" lower_limit="1203.3" upper_limit="1659.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n= 414, 405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="867" lower_limit="722.3" upper_limit="1039.6"/>
                    <measurement group_id="O2" value="1041" lower_limit="860.5" upper_limit="1260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n= 424, 419)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="651" lower_limit="582.4" upper_limit="728"/>
                    <measurement group_id="O2" value="670" lower_limit="599.7" upper_limit="748.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n= 419, 415)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="699" lower_limit="613.7" upper_limit="797.2"/>
                    <measurement group_id="O2" value="838" lower_limit="734.2" upper_limit="957.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n= 421, 416)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="574" lower_limit="496.8" upper_limit="663"/>
                    <measurement group_id="O2" value="760" lower_limit="665.6" upper_limit="868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n= 420, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="713" lower_limit="598.9" upper_limit="849.9"/>
                    <measurement group_id="O2" value="865" lower_limit="726.4" upper_limit="1030.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n= 425, 419)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337" lower_limit="294.9" upper_limit="384.6"/>
                    <measurement group_id="O2" value="390" lower_limit="344.4" upper_limit="441.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n= 423, 416)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324" lower_limit="274.8" upper_limit="382.5"/>
                    <measurement group_id="O2" value="360" lower_limit="302.7" upper_limit="427.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n= 421, 417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278" lower_limit="223.9" upper_limit="344.7"/>
                    <measurement group_id="O2" value="364" lower_limit="294.3" upper_limit="451.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: Confidence Intervals (CIs) for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: Confidence Intervals (CIs) for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: Confidence Intervals (CIs) for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: Confidence Intervals (CIs) for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: Confidence Intervals (CIs) for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: Confidence Intervals (CIs) for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: Confidence Intervals (CIs) for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: Confidence Intervals (CIs) for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: Confidence Intervals (CIs) for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: Confidence Intervals (CIs) for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: Confidence Intervals (CIs) for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: Confidence Intervals (CIs) for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: Confidence Intervals (CIs) for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemagglutination Inhibition Assay (HAI) Geometric Mean Titers (GMTs) for Each Influenza Virus Strain in Quadrivalent Influenza Vaccine (QIV)</title>
        <description>HAI GMTs were computed for assay titers collected 1 month after Vaccination 1 by vaccine sequence for each influenza virus strain (A/H1N1, A/H3N2, B/Brisbane and B/Massachusetts). CIs were back-transformations of a CI based on the Student t distribution for the mean logarithm of the titers. HAI GMTs were calculated using all participants with available data for the specified blood draw. Here, &quot;number of participants analyzed&quot; signifies participants with a determinate HAI titer to the given strain.</description>
        <time_frame>1 month after Vaccination 1</time_frame>
        <population>Evaluable immunogenicity population: eligible, randomized participants of 50 years of age or above, received all study vaccinations in assigned sequence with expected concomitant vaccination, had at least 1 valid, determinate assay results, had pre and post vaccination blood drawn within protocol-specified time frames, no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC+QIV/Placebo</title>
            <description>Participants received 0.5 milliliter (mL) single dose of 13-valent pneumococcal conjugate (13vPnC) vaccine intramuscularly along with a dose of quadrivalent influenza vaccine (QIV, as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+QIV/13vPnC</title>
            <description>Participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection as per official recommendations at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition Assay (HAI) Geometric Mean Titers (GMTs) for Each Influenza Virus Strain in Quadrivalent Influenza Vaccine (QIV)</title>
          <description>HAI GMTs were computed for assay titers collected 1 month after Vaccination 1 by vaccine sequence for each influenza virus strain (A/H1N1, A/H3N2, B/Brisbane and B/Massachusetts). CIs were back-transformations of a CI based on the Student t distribution for the mean logarithm of the titers. HAI GMTs were calculated using all participants with available data for the specified blood draw. Here, &quot;number of participants analyzed&quot; signifies participants with a determinate HAI titer to the given strain.</description>
          <population>Evaluable immunogenicity population: eligible, randomized participants of 50 years of age or above, received all study vaccinations in assigned sequence with expected concomitant vaccination, had at least 1 valid, determinate assay results, had pre and post vaccination blood drawn within protocol-specified time frames, no major protocol violations.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain: A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" lower_limit="104.0" upper_limit="126.8"/>
                    <measurement group_id="O2" value="113" lower_limit="101.6" upper_limit="124.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain: A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226" lower_limit="206.1" upper_limit="248.5"/>
                    <measurement group_id="O2" value="196" lower_limit="178.0" upper_limit="216.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain: B/Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="25.7" upper_limit="31.0"/>
                    <measurement group_id="O2" value="26" lower_limit="23.7" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain: B/Massachusetts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="41.0" upper_limit="50.3"/>
                    <measurement group_id="O2" value="43" lower_limit="39.1" upper_limit="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Strain A/H1N1: CIs for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Strain A/H3N2: CIs for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Strain B/Brisbane: CIs for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Strain B/Massachusetts: CIs for the ratio were back transformations of CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC+QIV/placebo – placebo+QIV/13vPnC).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-­Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 1</title>
        <description>An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).</description>
        <time_frame>Within 28 to 42 days after Vaccination 1</time_frame>
        <population>Safety population included all participants who received at least 1 dose of vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC+QIV/Placebo</title>
            <description>Participants received 0.5 milliliter (mL) single dose of 13-valent pneumococcal conjugate (13vPnC) vaccine intramuscularly along with a dose of quadrivalent influenza vaccine (QIV, as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+QIV/13vPnC</title>
            <description>Participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection as per official recommendations at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-­Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 1</title>
          <description>An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).</description>
          <population>Safety population included all participants who received at least 1 dose of vaccination.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="439"/>
                <count group_id="O2" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-­Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 2</title>
        <description>An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).</description>
        <time_frame>Within 28 to 42 days after Vaccination 2</time_frame>
        <population>Safety population included all participants who received at least 1 dose of vaccination. Here, &quot;number of participants analyzed&quot; signifies participants who were evaluable at this timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC+QIV/Placebo</title>
            <description>Participants received 0.5 milliliter (mL) single dose of 13-valent pneumococcal conjugate (13vPnC) vaccine intramuscularly along with a dose of quadrivalent influenza vaccine (QIV, as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+QIV/13vPnC</title>
            <description>Participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection as per official recommendations at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-­Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 2</title>
          <description>An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).</description>
          <population>Safety population included all participants who received at least 1 dose of vaccination. Here, &quot;number of participants analyzed&quot; signifies participants who were evaluable at this timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-­Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After 13vPnC Vaccination</title>
        <description>An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).</description>
        <time_frame>Baseline (Vaccination 1) up to 28 to 42 Days after Vaccination 2</time_frame>
        <population>Safety population included all participants who received at least 1 dose of vaccination. Here, &quot;number of participants analyzed&quot; signifies participants who were evaluable at this timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC+QIV/Placebo</title>
            <description>Participants received 0.5 milliliter (mL) single dose of 13-valent pneumococcal conjugate (13vPnC) vaccine intramuscularly along with a dose of quadrivalent influenza vaccine (QIV, as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+QIV/13vPnC</title>
            <description>Participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection as per official recommendations at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-­Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After 13vPnC Vaccination</title>
          <description>An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).</description>
          <population>Safety population included all participants who received at least 1 dose of vaccination. Here, &quot;number of participants analyzed&quot; signifies participants who were evaluable at this timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="439"/>
                <count group_id="O2" value="432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AE: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC+QIV /placebo – placebo+QIV/13vPnC, expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SAE: Exact 2-sided confidence interval (based on Chan and Zhang) for the difference in proportions, 13vPnC+QIV /placebo – placebo+QIV/13vPnC, expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-­Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) at the 6-Month Follow-up</title>
        <description>An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).</description>
        <time_frame>Within 168 to 196 days after Vaccination 2</time_frame>
        <population>Safety population included all participants who received at least 1 dose of vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC+QIV/Placebo</title>
            <description>Participants received 0.5 milliliter (mL) single dose of 13-valent pneumococcal conjugate (13vPnC) vaccine intramuscularly along with a dose of quadrivalent influenza vaccine (QIV, as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+QIV/13vPnC</title>
            <description>Participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection as per official recommendations at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-­Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) at the 6-Month Follow-up</title>
          <description>An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).</description>
          <population>Safety population included all participants who received at least 1 dose of vaccination.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="439"/>
                <count group_id="O2" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibody Titer Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ)</title>
        <description>Percentage of participants achieving predefined OPA antibody titer &gt;= LLOQ for each of the 13 pneumococcal serotypes (LLOQs for each serotype OPA were set as- serotype 1: 18; serotype 3: 12; serotype 4: 21; serotype 5: 29; serotype 6A: 37; serotype 6B: 43; serotype 7F: 210; serotype 9V: 345; serotype 14: 35; serotype 18C: 31; serotype 19A: 18; serotype 19F: 48; and serotype 23F: 13) determined in blood samples of all participants were calculated. Exact, 2-sided 95% CIs based on the observed percentage of participants were determined by using Clopper and Pearson method. OPA titers were calculated using all participants with available data from 1 month after 13vPnC vaccination blood draw. Here, &quot;number of participants analyzed&quot; signifies the participants who were evaluable at this timepoint and &quot;n&quot; signifies participants with valid and determinate assay results to the specified serotype.</description>
        <time_frame>1 Month After Vaccination 1 for 13vPnC+QIV/Placebo, 1 month after Vaccination 2 for Placebo+QIV/13vPnC</time_frame>
        <population>Evaluable immunogenicity population: eligible, randomized participants of 50 years of age or above, received all study vaccinations in assigned sequence with expected concomitant vaccination, had at least 1 valid, determinate assay results, had pre and post vaccination blood drawn within protocol-specified time frames, no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC+QIV/Placebo</title>
            <description>Participants received 0.5 milliliter (mL) single dose of 13-valent pneumococcal conjugate (13vPnC) vaccine intramuscularly along with a dose of quadrivalent influenza vaccine (QIV, as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+QIV/13vPnC</title>
            <description>Participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection as per official recommendations at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibody Titer Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ)</title>
          <description>Percentage of participants achieving predefined OPA antibody titer &gt;= LLOQ for each of the 13 pneumococcal serotypes (LLOQs for each serotype OPA were set as- serotype 1: 18; serotype 3: 12; serotype 4: 21; serotype 5: 29; serotype 6A: 37; serotype 6B: 43; serotype 7F: 210; serotype 9V: 345; serotype 14: 35; serotype 18C: 31; serotype 19A: 18; serotype 19F: 48; and serotype 23F: 13) determined in blood samples of all participants were calculated. Exact, 2-sided 95% CIs based on the observed percentage of participants were determined by using Clopper and Pearson method. OPA titers were calculated using all participants with available data from 1 month after 13vPnC vaccination blood draw. Here, &quot;number of participants analyzed&quot; signifies the participants who were evaluable at this timepoint and &quot;n&quot; signifies participants with valid and determinate assay results to the specified serotype.</description>
          <population>Evaluable immunogenicity population: eligible, randomized participants of 50 years of age or above, received all study vaccinations in assigned sequence with expected concomitant vaccination, had at least 1 valid, determinate assay results, had pre and post vaccination blood drawn within protocol-specified time frames, no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n= 419, 417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" lower_limit="73.0" upper_limit="81.3"/>
                    <measurement group_id="O2" value="80.1" lower_limit="75.9" upper_limit="83.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n= 422, 418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.4" lower_limit="75.2" upper_limit="83.1"/>
                    <measurement group_id="O2" value="83.7" lower_limit="79.8" upper_limit="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n= 412, 417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6" lower_limit="85.1" upper_limit="91.5"/>
                    <measurement group_id="O2" value="92.1" lower_limit="89.1" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n= 423, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" lower_limit="70.0" upper_limit="78.6"/>
                    <measurement group_id="O2" value="72.7" lower_limit="68.1" upper_limit="76.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n= 420, 415)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" lower_limit="87.3" upper_limit="93.1"/>
                    <measurement group_id="O2" value="94.2" lower_limit="91.5" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n= 414, 405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" lower_limit="81.2" upper_limit="88.3"/>
                    <measurement group_id="O2" value="86.4" lower_limit="82.7" upper_limit="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n= 424, 419)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3" lower_limit="78.3" upper_limit="85.8"/>
                    <measurement group_id="O2" value="83.5" lower_limit="79.6" upper_limit="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n= 419, 415)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2" lower_limit="60.4" upper_limit="69.7"/>
                    <measurement group_id="O2" value="71.3" lower_limit="66.7" upper_limit="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n= 421, 416)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" lower_limit="88.4" upper_limit="93.9"/>
                    <measurement group_id="O2" value="95.2" lower_limit="92.7" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n= 420, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.8" lower_limit="85.4" upper_limit="91.7"/>
                    <measurement group_id="O2" value="91.3" lower_limit="88.2" upper_limit="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n= 425, 419)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" lower_limit="93.1" upper_limit="97.3"/>
                    <measurement group_id="O2" value="97.4" lower_limit="95.4" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n= 423, 416)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9" lower_limit="75.8" upper_limit="83.6"/>
                    <measurement group_id="O2" value="79.6" lower_limit="75.4" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n= 421, 417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3" lower_limit="76.2" upper_limit="84.0"/>
                    <measurement group_id="O2" value="84.2" lower_limit="80.3" upper_limit="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.333</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.3</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.105</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.6</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.090</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.6</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.590</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>7.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.5</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.574</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.2</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.648</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.3</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-6.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.5</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.233</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.152</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.926</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.143</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 1 to Immediately Before 13vPnC Vaccination 1</title>
        <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 1 month after Vaccination 1 to before Vaccination 1 were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before Vaccination 1 and 1 month after Vaccination 1 blood draws. Here, &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both the given visits. Number of participants who received at least 1 dose of 13vPnC during Vaccination 1 were analyzed.</description>
        <time_frame>Immediately before Vaccination 1, 1 month after Vaccination 1</time_frame>
        <population>Evaluable immunogenicity population: eligible, randomized participants of 50 years of age or above, received all study vaccinations in assigned sequence with expected concomitant vaccination, had at least 1 valid, determinate assay results, had pre and post vaccination blood drawn within protocol-specified time frames, no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC+QIV/Placebo</title>
            <description>Participants received 0.5 milliliter (mL) single dose of 13-valent pneumococcal conjugate (13vPnC) vaccine intramuscularly along with a dose of quadrivalent influenza vaccine (QIV, as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 1 to Immediately Before 13vPnC Vaccination 1</title>
          <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 1 month after Vaccination 1 to before Vaccination 1 were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before Vaccination 1 and 1 month after Vaccination 1 blood draws. Here, &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both the given visits. Number of participants who received at least 1 dose of 13vPnC during Vaccination 1 were analyzed.</description>
          <population>Evaluable immunogenicity population: eligible, randomized participants of 50 years of age or above, received all study vaccinations in assigned sequence with expected concomitant vaccination, had at least 1 valid, determinate assay results, had pre and post vaccination blood drawn within protocol-specified time frames, no major protocol violations.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n= 417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="3.20" upper_limit="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n= 419)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="3.05" upper_limit="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n= 399)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="7.33" upper_limit="11.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n= 422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.70" upper_limit="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n= 408)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" lower_limit="11.30" upper_limit="16.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n= 391)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="7.29" upper_limit="10.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n= 417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.40" upper_limit="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n= 405)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.92" upper_limit="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n= 411)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.78" upper_limit="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n= 417)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.38" upper_limit="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n= 424)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="3.20" upper_limit="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n= 419)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.60" upper_limit="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n= 418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="7.07" upper_limit="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 2 to Immediately Before 13vPnC Vaccination 2</title>
        <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 1 month after Vaccination 2 to before Vaccination 2 (1 month after Vaccination 1) were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before Vaccination 2 and 1 month after Vaccination 2 blood draws. Here, &quot;number of participants analyzed&quot; signifies total participants who were evaluable at this timepoint and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both the given visits. Number of participants who received at least 1 dose of 13vPnC during Vaccination 2 were analyzed.</description>
        <time_frame>Immediately before Vaccination 2, 1 month after Vaccination 2</time_frame>
        <population>Evaluable immunogenicity population: eligible, randomized participants of 50 years of age or above, received all study vaccinations in assigned sequence with expected concomitant vaccination, had at least 1 valid, determinate assay results, had pre and post vaccination blood drawn within protocol-specified time frames, no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo+QIV/13vPnC</title>
            <description>Participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection as per official recommendations at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 2 to Immediately Before 13vPnC Vaccination 2</title>
          <description>GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 1 month after Vaccination 2 to before Vaccination 2 (1 month after Vaccination 1) were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before Vaccination 2 and 1 month after Vaccination 2 blood draws. Here, &quot;number of participants analyzed&quot; signifies total participants who were evaluable at this timepoint and &quot;n&quot; signifies participants with valid and determinate assay results for specified serotype at both the given visits. Number of participants who received at least 1 dose of 13vPnC during Vaccination 2 were analyzed.</description>
          <population>Evaluable immunogenicity population: eligible, randomized participants of 50 years of age or above, received all study vaccinations in assigned sequence with expected concomitant vaccination, had at least 1 valid, determinate assay results, had pre and post vaccination blood drawn within protocol-specified time frames, no major protocol violations.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1 (n =413)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="3.19" upper_limit="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 (n= 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="3.47" upper_limit="4.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 (n= 391)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="8.28" upper_limit="12.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5 (n= 411)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.87" upper_limit="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A (n= 399)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" lower_limit="14.73" upper_limit="21.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n= 382)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="7.69" upper_limit="11.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F (n= 407)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.41" upper_limit="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n= 399)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="2.12" upper_limit="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n= 406)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.98" upper_limit="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n= 408)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="5.21" upper_limit="7.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A (n= 416)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="4.02" upper_limit="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n= 410)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="4.12" upper_limit="5.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n= 412)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="10.42" upper_limit="15.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Seroconversion in Hemagglutination Inhibition Assay (HAI) Titers</title>
        <description>Percentage of participants achieving seroconversion in HAI titers was defined as the percentage of participants with either before Vaccination 1 (pre-vaccination 1) HAI titer less than &lt;1:10 and after Vaccination 1 (post-vaccination 1) HAI titer &gt;=1:40 or before Vaccination 1 (pre-vaccination 1) HAI titer &gt;=1:10 and a minimum 4-fold rise in after Vaccination 1 (post-vaccination 1) HAI antibody titer with respect to before Vaccination 1 (pre-vaccination) titer for influenza virus strains. Here, &quot;number of participants analyzed&quot; signifies the participants who were evaluable at this timepoint.</description>
        <time_frame>Immediately before Vaccination 1, 1 month after Vaccination 1</time_frame>
        <population>Evaluable immunogenicity population: eligible, randomized participants of 50 years of age or above, received all study vaccinations in assigned sequence with expected concomitant vaccination, had at least 1 valid, determinate assay results, had pre and post vaccination blood drawn within protocol-specified time frames, no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC+QIV/Placebo</title>
            <description>Participants received 0.5 milliliter (mL) single dose of 13-valent pneumococcal conjugate (13vPnC) vaccine intramuscularly along with a dose of quadrivalent influenza vaccine (QIV, as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+QIV/13vPnC</title>
            <description>Participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection as per official recommendations at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Seroconversion in Hemagglutination Inhibition Assay (HAI) Titers</title>
          <description>Percentage of participants achieving seroconversion in HAI titers was defined as the percentage of participants with either before Vaccination 1 (pre-vaccination 1) HAI titer less than &lt;1:10 and after Vaccination 1 (post-vaccination 1) HAI titer &gt;=1:40 or before Vaccination 1 (pre-vaccination 1) HAI titer &gt;=1:10 and a minimum 4-fold rise in after Vaccination 1 (post-vaccination 1) HAI antibody titer with respect to before Vaccination 1 (pre-vaccination) titer for influenza virus strains. Here, &quot;number of participants analyzed&quot; signifies the participants who were evaluable at this timepoint.</description>
          <population>Evaluable immunogenicity population: eligible, randomized participants of 50 years of age or above, received all study vaccinations in assigned sequence with expected concomitant vaccination, had at least 1 valid, determinate assay results, had pre and post vaccination blood drawn within protocol-specified time frames, no major protocol violations.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain: A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" lower_limit="25.0" upper_limit="33.8"/>
                    <measurement group_id="O2" value="24.2" lower_limit="20.2" upper_limit="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain: A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" lower_limit="23.7" upper_limit="32.4"/>
                    <measurement group_id="O2" value="31.6" lower_limit="27.3" upper_limit="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain: B/Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" lower_limit="17.5" upper_limit="25.5"/>
                    <measurement group_id="O2" value="22.3" lower_limit="18.5" upper_limit="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain: B/Massachusetts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" lower_limit="19.3" upper_limit="27.5"/>
                    <measurement group_id="O2" value="24.7" lower_limit="20.6" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Strain A/H1N1: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <p_value>0.094</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>11.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Strain A/H3N2: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <p_value>0.232</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.9</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Strain B/Brisbane: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <p_value>0.734</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Strain B/Massachusetts: Exact 2-sided CI and corresponding p-value (based on Chan and Zhang) for the difference in proportions, (13vPnC+QIV/placebo – placebo+QIV/13vPnC), expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criterion for noninferiority was the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.5 (2-fold criterion).</non_inferiority_desc>
            <p_value>0.627</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) in Hemagglutination Inhibition Assay (HAI) 1 Month After Vaccination 1 to Immediately Before Vaccination 1</title>
        <description>Fold rise 1 month after Vaccination 1 to before Vaccination 1 was calculated for each influenza virus strain (A/H1N1, A/H3N2, B/Brisbane and B/Massachusetts). GMFRs were calculated using all participants with available data from both the specified blood draws. CI for the GMFRs were back transformations of a CI based on the Student t distribution for mean fold rise. Here, &quot;number of participants analyzed&quot; signifies participants with valid and determinate assay results for specified strain at both the specified blood draws.</description>
        <time_frame>Immediately before Vaccination 1, 1 month after Vaccination 1</time_frame>
        <population>Evaluable immunogenicity population: eligible, randomized participants of 50 years of age or above, received all study vaccinations in assigned sequence with expected concomitant vaccination, had at least 1 valid, determinate assay results, had pre and post vaccination blood drawn within protocol-specified time frames, no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC+QIV/Placebo</title>
            <description>Participants received 0.5 milliliter (mL) single dose of 13-valent pneumococcal conjugate (13vPnC) vaccine intramuscularly along with a dose of quadrivalent influenza vaccine (QIV, as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo+QIV/13vPnC</title>
            <description>Participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection as per official recommendations at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) in Hemagglutination Inhibition Assay (HAI) 1 Month After Vaccination 1 to Immediately Before Vaccination 1</title>
          <description>Fold rise 1 month after Vaccination 1 to before Vaccination 1 was calculated for each influenza virus strain (A/H1N1, A/H3N2, B/Brisbane and B/Massachusetts). GMFRs were calculated using all participants with available data from both the specified blood draws. CI for the GMFRs were back transformations of a CI based on the Student t distribution for mean fold rise. Here, &quot;number of participants analyzed&quot; signifies participants with valid and determinate assay results for specified strain at both the specified blood draws.</description>
          <population>Evaluable immunogenicity population: eligible, randomized participants of 50 years of age or above, received all study vaccinations in assigned sequence with expected concomitant vaccination, had at least 1 valid, determinate assay results, had pre and post vaccination blood drawn within protocol-specified time frames, no major protocol violations.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strain: A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="2.17" upper_limit="2.64"/>
                    <measurement group_id="O2" value="2.2" lower_limit="2.01" upper_limit="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain: A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="2.09" upper_limit="2.51"/>
                    <measurement group_id="O2" value="2.4" lower_limit="2.15" upper_limit="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain: B/Brisbane</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.97" upper_limit="2.32"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.98" upper_limit="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strain: B/Massachusetts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.98" upper_limit="2.34"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.98" upper_limit="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>13vPnC+QIV/Placebo: After Vaccination 1</title>
          <description>All participants received 0.5 mL single dose of 13vPnC vaccine intramuscularly along with a dose of QIV (as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1, were assessed from Vaccination 1 up to before Vaccination 2.</description>
        </group>
        <group group_id="E2">
          <title>Placebo+QIV/13vPnC: After Vaccination 1</title>
          <description>All participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection (as per official recommendations) at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1, were accessed from Vaccination 1 up to before Vaccination 2.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC+QIV/Placebo: After Vaccination 2</title>
          <description>All participants received 0.5 mL single dose of 13vPnC vaccine intramuscularly along with a dose of QIV (as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1, were assessed from after Vaccination 2 up to before 1 month blood draw after Vaccination 2.</description>
        </group>
        <group group_id="E4">
          <title>Placebo+QIV/13vPnC: After Vaccination 2</title>
          <description>All participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection (as per official recommendations) at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1, were assessed from after Vaccination 2 up to before 1 month blood draw after Vaccination 2.</description>
        </group>
        <group group_id="E5">
          <title>13vPnC+QIV/Placebo: After 13vPnC Vaccination</title>
          <description>All participants received 0.5 mL single dose of 13vPnC vaccine intramuscularly along with a dose of QIV (as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1, were assessed after 13vPnC Vaccination.</description>
        </group>
        <group group_id="E6">
          <title>Placebo+QIV/13vPnC: After 13vPnC Vaccination</title>
          <description>All participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection (as per official recommendations) at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1, were assessed after 13vPnC Vaccination.</description>
        </group>
        <group group_id="E7">
          <title>13vPnC+QIV/Placebo: at 6-Month Follow-up</title>
          <description>All participants received 0.5 mL single dose of 13vPnC vaccine intramuscularly along with a dose of QIV (as per official recommendations) intramuscularly at Day 1 (Vaccination 1) followed by 0.5 mL placebo matched to 13vPnC vaccine intramuscularly 1 month after Vaccination 1, were assessed from blood draw 1 month blood after Vaccination 2 to 6-month follow-up.</description>
        </group>
        <group group_id="E8">
          <title>Placebo+QIV/13vPnC: at 6-Month Follow-up</title>
          <description>All participants received 0.5 mL placebo matched to 13vPnC vaccine intramuscularly along with a dose of QIV intramuscular injection (as per official recommendations) at Day 1 (Vaccination 1) followed by 0.5 mL single dose of 13vPnC vaccine intramuscularly 1 month after Vaccination 1, were assessed from blood draw 1 month blood after Vaccination 2 to 6-month follow-up.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Surgical failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Bone loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="62" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="51" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Loose tooth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Vaccination site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Vaccination site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Groin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Chemical burn of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Chemical burns of eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Splinter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pelvic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pulmonary pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="439"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="439"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="437"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-­800­-718­-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

